Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-01-13 4:09 pm Sale |
2023-01-03 | 13D | Oyster Point Pharma, Inc. OYST |
Versant Venture Capital VI, L.P. | 0 0.000% |
-2,236,888 (Position Closed) |
Filing History |
| 2022-05-09 5:26 pm Purchase |
2022-04-29 | 13D | Tempest Therapeutics, Inc. TPST |
Versant Venture Capital VI, L.P. | 2,118,644 20.500% |
940,173 (+79.78%) |
Filing History |
| 2022-02-10 8:39 pm Purchase |
2021-12-31 | 13G | Century Therapeutics, Inc. IPSC |
Versant Venture Capital VI, L.P. | 12,366,814 22.600% |
12,366,814 (New Position) |
Filing History |
| 2022-02-10 7:41 pm Purchase |
2021-12-31 | 13G | Tempest Therapeutics, Inc. TPST |
Versant Venture Capital VI, L.P. | 1,178,471 17.100% |
1,178,471 (New Position) |
Filing History |
| 2022-01-13 4:34 pm Unchanged |
2022-01-05 | 13D | Oyster Point Pharma, Inc. OYST |
Versant Venture Capital VI, L.P. | 2,236,888 8.500% |
0 (Unchanged) |
Filing History |
| 2021-10-27 4:32 pm Unchanged |
2021-10-18 | 13D | Oyster Point Pharma, Inc. OYST |
Versant Venture Capital VI, L.P. | 2,236,888 8.600% |
0 (Unchanged) |
Filing History |
| 2021-07-09 4:43 pm Purchase |
2021-06-29 | 13D | Graphite Bio, Inc. GRPH |
Versant Venture Capital VI, L.P. | 2,101,200 26.300% |
2,101,200 (New Position) |
Filing History |
| 2021-07-08 4:31 pm Purchase |
2021-06-28 | 13D | Monte Rosa Therapeutics, Inc. GLUE |
Versant Venture Capital VI, L.P. | 6,799,115 15.300% |
6,799,115 (New Position) |
Filing History |
| 2021-06-21 4:44 pm Sale |
2021-06-11 | 13D | Aligos Therapeutics, Inc. ALGS |
Versant Venture Capital VI, L.P. | 58,317 3.800% |
-19,439 (-25.00%) |
Filing History |
| 2021-05-24 4:27 pm Unchanged |
2021-05-12 | 13D | Oyster Point Pharma, Inc. OYST |
Versant Venture Capital VI, L.P. | 2,236,888 8.600% |
0 (Unchanged) |
Filing History |
| 2021-05-03 4:57 pm Sale |
2021-04-26 | 13D | Aligos Therapeutics, Inc. ALGS |
Versant Venture Capital VI, L.P. | 77,757 5.100% |
-19,439 (-20.00%) |
Filing History |
| 2021-04-08 4:31 pm Purchase |
2021-03-29 | 13D | LAVA Therapeutics N.V. LVTX |
Versant Venture Capital VI, L.P. | 3,407,157 13.400% |
3,407,157 (New Position) |
Filing History |
| 2021-04-05 4:33 pm Unchanged |
2021-03-26 | 13D | Oyster Point Pharma, Inc. OYST |
Versant Venture Capital VI, L.P. | 2,236,888 8.600% |
0 (Unchanged) |
Filing History |
| 2021-03-01 5:16 pm Sale |
2021-02-17 | 13D | Oyster Point Pharma, Inc. OYST |
Versant Venture Capital VI, L.P. | 2,236,888 8.600% |
-325,000 (-12.69%) |
Filing History |
| 2021-02-12 8:41 pm Sale |
2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
Versant Venture Capital VI, L.P. | 777,727 2.200% |
-2,878,858 (-78.73%) |
Filing History |
| 2020-12-03 4:47 pm Sale |
2020-11-23 | 13D | Black Diamond Therapeutics, Inc. BDTX |
Versant Venture Capital VI, L.P. | 4,328,883 12.000% |
-1,031,634 (-19.25%) |
Filing History |
| 2020-11-20 5:32 pm Sale |
2020-11-11 | 13D | Black Diamond Therapeutics, Inc. BDTX |
Versant Venture Capital VI, L.P. | 5,360,517 14.900% |
-980,734 (-15.47%) |
Filing History |
| 2020-10-30 4:25 pm Purchase |
2020-10-20 | 13D | Aligos Therapeutics, Inc. ALGS |
Versant Venture Capital VI, L.P. | 97,196 7.200% |
97,196 (New Position) |
Filing History |
| 2020-09-25 4:37 pm Sale |
2020-09-17 | 13D | Black Diamond Therapeutics, Inc. BDTX |
Versant Venture Capital VI, L.P. | 6,341,251 17.700% |
-457,424 (-6.73%) |
Filing History |
| 2020-08-21 4:19 pm Sale |
2020-08-12 | 13D | Black Diamond Therapeutics, Inc. BDTX |
Versant Venture Capital VI, L.P. | 6,798,675 18.900% |
-669,608 (-8.97%) |
Filing History |